BioPharma Resources

Drug Trial Radar · NCT07811908

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)

A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 12, 2026

Primary completion

Feb 4, 2027

Study completion Feb 18, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

  • KAE609Drug

    oral capsules administered in combination with KLU156

  • SoC (Coartem)Drug

    Standard of Care

  • KLU156Drug

    oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Polymerase chain reaction (PCR) corrected adequate clinical and parasitological response (ACPR)Time frame: Day 29

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Banfora, Burkina Faso · Recruiting

  • Novartis Investigative Site

    Nanoro, Burkina Faso · Recruiting

  • Novartis Investigative Site

    Abidjan, Côte d’Ivoire · Recruiting

  • Novartis Investigative Site

    Azaguié, Côte d’Ivoire · Recruiting

  • Novartis Investigative Site

    Lambaréné, Gabon · Not yet recruiting

  • Novartis Investigative Site

    Libreville, Gabon · Not yet recruiting

  • Novartis Investigative Site

    Kintampo, Ghana · Not yet recruiting

  • Novartis Investigative Site

    Navrongo, Ghana · Not yet recruiting

  • Novartis Investigative Site

    Ahero, Kenya · Not yet recruiting

  • Novartis Investigative Site

    Kisumu, Kenya · Not yet recruiting

  • Novartis Investigative Site

    Kigali, Rwanda · Recruiting

  • Novartis Investigative Site

    Kampala, Uganda · Not yet recruiting

  • Novartis Investigative Site

    Tororo, Uganda · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.